CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

PR Newswire

SUZHOU, China, June 25, 2026

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammation, and other key disease areas, today announced that it has entered into an exclusive commercialization agreement with Arrotex Pharmaceuticals Pty Ltd ("Arrotex"), a core pharmaceutical commercialization platform of DBG Health ("DBG"), Australia's largest diversified healthcare group, for the commercialization of sugemalimab in Australia and New Zealand.